Milne, Kate, Sturrock, Beattie and Chevassut, Timothy (2020) Chronic lymphocytic leukaemia in 2020: the future has arrived. Current Oncology Reports, 22. a36 1-9. ISSN 1523-3790
![]() |
Microsoft Word (DOCX) (Review)
Restricted to SRO admin only Download (119kB) |
![]() |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (359kB) |
Abstract
Purpose of Review
Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the treatment approaches used for these different subgroups.
Recent Findings
Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will be translated into durable remissions.
Summary
Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the majority of patients, early after diagnosis and with curative intent.
Item Type: | Article |
---|---|
Schools and Departments: | Brighton and Sussex Medical School > Clinical and Experimental Medicine |
Subjects: | R Medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens |
Depositing User: | Timothy Chevassut |
Date Deposited: | 23 Jun 2020 07:06 |
Last Modified: | 21 Feb 2022 13:53 |
URI: | http://sro.sussex.ac.uk/id/eprint/92079 |
View download statistics for this item
📧 Request an updateProject Name | Sussex Project Number | Funder | Funder Ref |
---|---|---|---|
Drug-induced selective lethality in populations of DNMT3A knockdown cells | G2782 | WELLCOME TRUST | 218435/Z/19/Z |
How does SARS CoV-2 infect blood vessels? | G3146 | UK RESEARCH AND INNOVATION | MR/V036750/1 |
In vitro modelling and therapeutic targeting of tumour cell migration in chronic lymphocytic leukaemia. | G2544 | BLOODWISE | Unset |
Mining the Wnt signalling-responsive surfaceome for drug targets in acute myeloid leukaemia | G3090 | WELLCOME TRUST | Unset |
Modelling and targeting Acute Myeloid Leukaemia cells in the Bone Marrow protective niche | G3106 | SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH | Unset |